1. Home
  2. NGNE vs WEYS Comparison

NGNE vs WEYS Comparison

Compare NGNE & WEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NGNE
  • WEYS
  • Stock Information
  • Founded
  • NGNE 2003
  • WEYS 1906
  • Country
  • NGNE United States
  • WEYS United States
  • Employees
  • NGNE N/A
  • WEYS N/A
  • Industry
  • NGNE Biotechnology: Pharmaceutical Preparations
  • WEYS Apparel
  • Sector
  • NGNE Health Care
  • WEYS Consumer Staples
  • Exchange
  • NGNE Nasdaq
  • WEYS Nasdaq
  • Market Cap
  • NGNE 325.3M
  • WEYS 299.8M
  • IPO Year
  • NGNE N/A
  • WEYS N/A
  • Fundamental
  • Price
  • NGNE $22.72
  • WEYS $31.68
  • Analyst Decision
  • NGNE Strong Buy
  • WEYS
  • Analyst Count
  • NGNE 7
  • WEYS 0
  • Target Price
  • NGNE $41.86
  • WEYS N/A
  • AVG Volume (30 Days)
  • NGNE 216.3K
  • WEYS 11.5K
  • Earning Date
  • NGNE 08-08-2025
  • WEYS 08-05-2025
  • Dividend Yield
  • NGNE N/A
  • WEYS 3.41%
  • EPS Growth
  • NGNE N/A
  • WEYS N/A
  • EPS
  • NGNE N/A
  • WEYS 3.04
  • Revenue
  • NGNE $925,000.00
  • WEYS $286,762,000.00
  • Revenue This Year
  • NGNE N/A
  • WEYS N/A
  • Revenue Next Year
  • NGNE N/A
  • WEYS N/A
  • P/E Ratio
  • NGNE N/A
  • WEYS $10.43
  • Revenue Growth
  • NGNE N/A
  • WEYS N/A
  • 52 Week Low
  • NGNE $6.88
  • WEYS $25.51
  • 52 Week High
  • NGNE $74.49
  • WEYS $41.05
  • Technical
  • Relative Strength Index (RSI)
  • NGNE 60.64
  • WEYS 45.55
  • Support Level
  • NGNE $20.80
  • WEYS $31.40
  • Resistance Level
  • NGNE $23.88
  • WEYS $33.33
  • Average True Range (ATR)
  • NGNE 1.44
  • WEYS 0.92
  • MACD
  • NGNE 0.09
  • WEYS -0.12
  • Stochastic Oscillator
  • NGNE 72.83
  • WEYS 14.60

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

Share on Social Networks: